Elastic NV vs Kymera Therapeutics Inc. Common Stock — how do they compare? Elastic NV trades at $90.77 (market cap $9.67B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: Elastic NV and Kymera Therapeutics Inc. Common Stock are close in size by market cap, and Elastic NV is trading nearer its 52-week high, Kymera Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 11 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| ESTC | KYMR | |
|---|---|---|
Market Cap | $9.67B | $8.87B |
Volume | 1,592,425 | 779,107 |
Sector | Technology | Health |
52-Week High | $99.91 | $127.31 |
52-Week Low | $43.30 | $55.80 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $8.80B | $8.26B |
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $94.32, down 1.26% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent product launches, including a metrics platform and serverless vector database, highlight innovation in AI and data search. Revenue grew to $1.48 billion in 2025, with a projected increase to $1.8 billion in 2026, though 2025 net income was negative.
The outlook is positive, driven by product innovation and earnings beats, but high valuation ratios and negative net income in 2025 pose risks. Analyst consensus is bullish with a $83.18 price target, suggesting potential upside. Key risks include execution challenges and competitive pressures in the software sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →